

## DELIVERY COMPLETES FIRST SALE OF APAS® PHARMAQC

APAS® PharmaQC delivered to Thermo Fisher Scientific

**Adelaide, Australia, 22 February 2024:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the delivery of APAS® PharmaQC to Thermo Fisher Scientific, Inc (**Thermo Fisher**).

### Highlights:

- **First recognised sale of APAS® PharmaQC for environmental monitoring application**
- **APAS® PharmaQC is currently being installed at one of Thermo Fisher Scientific's facilities**
- **Thermo Fisher is the global leader in serving science**

The Company has delivered an APAS® Independence instrument with APAS® PharmaQC software to a Thermo Fisher facility, reflecting the positive market interest from pharmaceutical customers following initial market development activities completed in the second half of calendar year 2023, coming approximately six months ahead of previous expectations. The Company has now established a pipeline of potential early adopters who have shown interest in the technology.

The delivery completes the sale of the instrument agreed as part of a strategic development partnership<sup>1</sup> with Thermo Fisher, providing funding for the development of APAS® PharmaQC to support their culture plate media for use in pharmaceutical microbial quality control applications. The APAS® PharmaQC technology aims to provide efficiencies and improve traceability within environmental monitoring workflows.

Brent Barnes, CEO & Managing Director said:

*"This is an important milestone for the Company, being the first deployment of APAS® PharmaQC outside of our partnership with AstraZeneca. The evaluation performed by Thermo Fisher will provide meaningful performance data supporting "real world" use of our technology. This will provide a further third-party validation of APAS® PharmaQC and further enhance our commercial activation of the product."*

Approved for release by the Chair of the LBT Board.

– ENDS –

### About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

### INVESTOR ENQUIRIES

<b>LBT Innovations</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>

<sup>1</sup> December 2022 ASX Announcement: LBT Strengthens APAS Pharma Development with Strategic Partnership. ([Link](#))